Effect of vutrisiran on components of health status in transthyretin amyloidosis with cardiomyopathy: the HELIOS-B study

20260 citationsJournal Articlehybrid Open Access

Authors

Yasuhiro Hamatani · Brigham and Women's Hospital

Brian L Claggett · Brigham and Women's Hospital

Muthiah Vaduganathan · Brigham and Women's Hospital

Sarah Birkhoelzer · Royal Bournemouth Hospital

Zi Michael Miao · Brigham and Women's Hospital

Farooq H Sheikh · Georgetown University

Emre Aldinc

Abstract

In HELIOS-B, vutrisiran was associated with improvement in a wide range of individual KCCQ components, with the greatest benefits observed in physical limitations and quality-of-life domains.

Topics & Keywords

Amyloidosis: Diagnosis, Treatment, Outcomes Parathyroid Disorders and Treatments Aortic Thrombus and Embolism

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: European Journal of Heart Failure

DOI: 10.1093/ejhf/xuag088

Field-Weighted Citation Impact: 0.00